

**TAB1 Antibody (Center) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP9382c****Specification**

---

**TAB1 Antibody (Center) Blocking Peptide - Product Information**Primary Accession [Q15750](#)**TAB1 Antibody (Center) Blocking Peptide - Additional Information****Gene ID** 10454**Other Names**

TGF-beta-activated kinase 1 and MAP3K7-binding protein 1, Mitogen-activated protein kinase kinase kinase 7-interacting protein 1, TGF-beta-activated kinase 1-binding protein 1, TAK1-binding protein 1, TAB1, MAP3K7IP1

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**TAB1 Antibody (Center) Blocking Peptide - Protein Information****Name** TAB1**Synonyms** MAP3K7IP1**Function**

Key adapter protein that plays an essential role in JNK and NF-kappa-B activation and proinflammatory cytokines production in response to stimulation with TLRs and cytokines (PubMed: [22307082](http://www.uniprot.org/citations/22307082), PubMed: [24403530](http://www.uniprot.org/citations/24403530)). Mechanistically, associates with the catalytic domain of MAP3K7/TAK1 to trigger MAP3K7/TAK1 autophosphorylation leading to its full activation (PubMed: [10838074](http://www.uniprot.org/citations/10838074), PubMed: [25260751](http://www.uniprot.org/citations/25260751), PubMed: [37832545](http://www.uniprot.org/citations/37832545)). Similarly, associates with MAPK14 and triggers its autophosphorylation and subsequent activation (PubMed: [11847341](http://www.uniprot.org/citations/11847341), PubMed: [29229647](http://www.uniprot.org/citations/29229647)). In turn, MAPK14 phosphorylates TAB1 and inhibits MAP3K7/TAK1 activation in a feedback control mechanism (PubMed: [14592977](http://www.uniprot.org/citations/14592977))

target="\_blank">14592977</a>). Plays also a role in recruiting MAPK14 to the TAK1 complex for the phosphorylation of the TAB2 and TAB3 regulatory subunits (PubMed:<a href="http://www.uniprot.org/citations/18021073" target="\_blank">18021073</a>).

**Cellular Location**

Cytoplasm, cytosol. Endoplasmic reticulum membrane; Peripheral membrane protein; Cytoplasmic side. Note=Recruited to the endoplasmic reticulum following interaction with STING1

**Tissue Location**

Ubiquitous..

**TAB1 Antibody (Center) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**TAB1 Antibody (Center) Blocking Peptide - Images****TAB1 Antibody (Center) Blocking Peptide - Background**

TAB1 was identified as a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli.

**TAB1 Antibody (Center) Blocking Peptide - References**

Isono, T., et al. Int. J. Oncol. 35(2):425-432(2009)Prickett, T.D., et al. J. Biol. Chem. 283(28):19245-19254(2008)Neil, J.R., et al. Cancer Res. 68(5):1462-1470(2008)Conner, S.H., et al. Biochem. J. 399(3):427-434(2006)Zhou, H., et al. Mol. Cell. Biol. 26(10):3824-3834(2006)Yamaguchi, K., et al. EMBO J. 18(1):179-187(1999)